research use only
Cat.No.S9744
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other PAR Inhibitors | FSLLRY-NH2 TFA I-191 ML161 (Parmodulin 2) SCH79797 dihydrochloride Atopaxar IUN76750 Trypsin TRAP-6 TFLLR-NH2 |
| Molecular Weight | 571.46 | Formula | C30H27BrN4O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2100284-59-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C1CCCCC1)[N]2C3=C(C=C(C=C3)C(=O)NC4=CC=C(C=C4)C#N)N=C2C5=C(Br)C=C6OCOC6=C5 | ||
|
In vitro |
DMSO
: 100 mg/mL
(174.99 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
PAR2
(Cell-free assay) 23 nM
|
|---|---|
| In vitro |
AZ3451 is a PAR2 antagonist that plays a part in inflammation response, apoptosis, autophagy and cellular senescence during Osteoarthritis (OA). This compound prevents the IL-1β-induced inflammation response, cartilage degradation and premature senescence in chondrocytes. It attenuates chondrocytes apoptosis by activating autophagy in vitro. The P38/MAPK, NF-κB and PI3K/AKT/mTOR pathways are involved in the protective effect of this chemical. |
| In vivo |
Intra-articular injection of AZ3451 can ameliorate the surgery induced cartilage degradation in rat Osteoarthritis (OA) model. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.